Relaxin decreases the severity of established hepatic fibrosis in mice

Robert G Bennett, Dean G. Heimann, Sudhir Singh, Ronda L. Simpson, Dean J. Tuma

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background & Aims: Hepatic fibrosis is characterized by excess collagen deposition, decreased extracellular matrix degradation and activation of the hepatic stellate cells. The hormone relaxin has shown promise in the treatment of fibrosis in a number of tissues, but the effect of relaxin on established hepatic fibrosis is unknown. The aim of this study was to determine the effect of relaxin on an in vivo model after establishing hepatic fibrosis Methods: Male mice were made fibrotic by carbon tetrachloride treatment for 4 weeks, followed by treatment with two doses of relaxin (25 or 75 μg/kg/day) or vehicle for 4 weeks, with continued administration of carbon tetrachloride. Results: Relaxin significantly decreased total hepatic collagen and smooth muscle actin content at both doses, and suppressed collagen I expression at the higher dose. Relaxin increased the expression of the matrix metalloproteinases MMP13 and MMP3, decreased the expression of MMP2 and tissue inhibitor of metalloproteinase 2 (TIMP2) and increased the overall level of collagen-degrading activity. Relaxin decreased TGFβ-induced Smad2 nuclear localization in mouse hepatic stellate cells. Conclusions: The results suggest that relaxin reduced collagen deposition and HSC activation in established hepatic fibrosis despite the presence of continued hepatic insult. This reduced fibrosis was associated with increased expression of the fibrillar collagen-degrading enzyme MMP13, decreased expression of TIMP2, and enhanced collagen-degrading activity, and impaired TGFβ signalling, consistent with relaxin's effects on activated fibroblastic cells. The results suggest that relaxin may be an effective treatment for the treatment of established hepatic fibrosis.

Original languageEnglish (US)
Pages (from-to)416-426
Number of pages11
JournalLiver International
Volume34
Issue number3
DOIs
StatePublished - Mar 1 2014

Fingerprint

Relaxin
Fibrosis
Liver
Collagen
Tissue Inhibitor of Metalloproteinase-2
Hepatic Stellate Cells
Carbon Tetrachloride
Fibrillar Collagens
Collagenases
Matrix Metalloproteinases
Extracellular Matrix
Smooth Muscle
Actins
Hormones

Keywords

  • Cirrhosis
  • Collagen
  • Hepatic stellate cells
  • Liver disease
  • Relaxin family peptides

ASJC Scopus subject areas

  • Hepatology

Cite this

Relaxin decreases the severity of established hepatic fibrosis in mice. / Bennett, Robert G; Heimann, Dean G.; Singh, Sudhir; Simpson, Ronda L.; Tuma, Dean J.

In: Liver International, Vol. 34, No. 3, 01.03.2014, p. 416-426.

Research output: Contribution to journalArticle

Bennett, RG, Heimann, DG, Singh, S, Simpson, RL & Tuma, DJ 2014, 'Relaxin decreases the severity of established hepatic fibrosis in mice', Liver International, vol. 34, no. 3, pp. 416-426. https://doi.org/10.1111/liv.12247
Bennett, Robert G ; Heimann, Dean G. ; Singh, Sudhir ; Simpson, Ronda L. ; Tuma, Dean J. / Relaxin decreases the severity of established hepatic fibrosis in mice. In: Liver International. 2014 ; Vol. 34, No. 3. pp. 416-426.
@article{ac1336ae06a94a0d82f8d884f6e3cf10,
title = "Relaxin decreases the severity of established hepatic fibrosis in mice",
abstract = "Background & Aims: Hepatic fibrosis is characterized by excess collagen deposition, decreased extracellular matrix degradation and activation of the hepatic stellate cells. The hormone relaxin has shown promise in the treatment of fibrosis in a number of tissues, but the effect of relaxin on established hepatic fibrosis is unknown. The aim of this study was to determine the effect of relaxin on an in vivo model after establishing hepatic fibrosis Methods: Male mice were made fibrotic by carbon tetrachloride treatment for 4 weeks, followed by treatment with two doses of relaxin (25 or 75 μg/kg/day) or vehicle for 4 weeks, with continued administration of carbon tetrachloride. Results: Relaxin significantly decreased total hepatic collagen and smooth muscle actin content at both doses, and suppressed collagen I expression at the higher dose. Relaxin increased the expression of the matrix metalloproteinases MMP13 and MMP3, decreased the expression of MMP2 and tissue inhibitor of metalloproteinase 2 (TIMP2) and increased the overall level of collagen-degrading activity. Relaxin decreased TGFβ-induced Smad2 nuclear localization in mouse hepatic stellate cells. Conclusions: The results suggest that relaxin reduced collagen deposition and HSC activation in established hepatic fibrosis despite the presence of continued hepatic insult. This reduced fibrosis was associated with increased expression of the fibrillar collagen-degrading enzyme MMP13, decreased expression of TIMP2, and enhanced collagen-degrading activity, and impaired TGFβ signalling, consistent with relaxin's effects on activated fibroblastic cells. The results suggest that relaxin may be an effective treatment for the treatment of established hepatic fibrosis.",
keywords = "Cirrhosis, Collagen, Hepatic stellate cells, Liver disease, Relaxin family peptides",
author = "Bennett, {Robert G} and Heimann, {Dean G.} and Sudhir Singh and Simpson, {Ronda L.} and Tuma, {Dean J.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1111/liv.12247",
language = "English (US)",
volume = "34",
pages = "416--426",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Relaxin decreases the severity of established hepatic fibrosis in mice

AU - Bennett, Robert G

AU - Heimann, Dean G.

AU - Singh, Sudhir

AU - Simpson, Ronda L.

AU - Tuma, Dean J.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Background & Aims: Hepatic fibrosis is characterized by excess collagen deposition, decreased extracellular matrix degradation and activation of the hepatic stellate cells. The hormone relaxin has shown promise in the treatment of fibrosis in a number of tissues, but the effect of relaxin on established hepatic fibrosis is unknown. The aim of this study was to determine the effect of relaxin on an in vivo model after establishing hepatic fibrosis Methods: Male mice were made fibrotic by carbon tetrachloride treatment for 4 weeks, followed by treatment with two doses of relaxin (25 or 75 μg/kg/day) or vehicle for 4 weeks, with continued administration of carbon tetrachloride. Results: Relaxin significantly decreased total hepatic collagen and smooth muscle actin content at both doses, and suppressed collagen I expression at the higher dose. Relaxin increased the expression of the matrix metalloproteinases MMP13 and MMP3, decreased the expression of MMP2 and tissue inhibitor of metalloproteinase 2 (TIMP2) and increased the overall level of collagen-degrading activity. Relaxin decreased TGFβ-induced Smad2 nuclear localization in mouse hepatic stellate cells. Conclusions: The results suggest that relaxin reduced collagen deposition and HSC activation in established hepatic fibrosis despite the presence of continued hepatic insult. This reduced fibrosis was associated with increased expression of the fibrillar collagen-degrading enzyme MMP13, decreased expression of TIMP2, and enhanced collagen-degrading activity, and impaired TGFβ signalling, consistent with relaxin's effects on activated fibroblastic cells. The results suggest that relaxin may be an effective treatment for the treatment of established hepatic fibrosis.

AB - Background & Aims: Hepatic fibrosis is characterized by excess collagen deposition, decreased extracellular matrix degradation and activation of the hepatic stellate cells. The hormone relaxin has shown promise in the treatment of fibrosis in a number of tissues, but the effect of relaxin on established hepatic fibrosis is unknown. The aim of this study was to determine the effect of relaxin on an in vivo model after establishing hepatic fibrosis Methods: Male mice were made fibrotic by carbon tetrachloride treatment for 4 weeks, followed by treatment with two doses of relaxin (25 or 75 μg/kg/day) or vehicle for 4 weeks, with continued administration of carbon tetrachloride. Results: Relaxin significantly decreased total hepatic collagen and smooth muscle actin content at both doses, and suppressed collagen I expression at the higher dose. Relaxin increased the expression of the matrix metalloproteinases MMP13 and MMP3, decreased the expression of MMP2 and tissue inhibitor of metalloproteinase 2 (TIMP2) and increased the overall level of collagen-degrading activity. Relaxin decreased TGFβ-induced Smad2 nuclear localization in mouse hepatic stellate cells. Conclusions: The results suggest that relaxin reduced collagen deposition and HSC activation in established hepatic fibrosis despite the presence of continued hepatic insult. This reduced fibrosis was associated with increased expression of the fibrillar collagen-degrading enzyme MMP13, decreased expression of TIMP2, and enhanced collagen-degrading activity, and impaired TGFβ signalling, consistent with relaxin's effects on activated fibroblastic cells. The results suggest that relaxin may be an effective treatment for the treatment of established hepatic fibrosis.

KW - Cirrhosis

KW - Collagen

KW - Hepatic stellate cells

KW - Liver disease

KW - Relaxin family peptides

UR - http://www.scopus.com/inward/record.url?scp=84893793330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893793330&partnerID=8YFLogxK

U2 - 10.1111/liv.12247

DO - 10.1111/liv.12247

M3 - Article

C2 - 23870027

AN - SCOPUS:84893793330

VL - 34

SP - 416

EP - 426

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 3

ER -